Cell line for producing a non-retroviral vector

Abstract

Provided are novel vectors and viral vectors capable of expressing exogenous gene or exogenous nucleic acid sequences in a target cell of interest, such as T cells, bone marrow cells, epithelial cells, liver cells and the like. The nucleic acid components of the vectors may include one or more native promoter/enhancer regions having modified sequence segments, one or more non-native promoter/enhancer or non-native promoter's gene or gene segment, and a native viral vector terminator or processing signal or segment thereof. The viral vectors comprise a virus or viral portion having on the surfaces or envelopes adsorption components, one for a packaging cell line and the other for delivery to a target cell. Other viral vectors provided by this invention have two components on their surfaces or envelopes, one of which is native to the virus and the other being non-native and capable of adsorbing to the target cell while being incapable of adsorbing to a native cell for the viral vector. Packaging cell lines for propagating the vectors and viral vectors are also provided, as are novel processes for propagating any of the disclosed vectors or viral vectors.

1 - 67 . (canceled) 
     
     
         68 . A cell line comprising:
 i) retroviral sequences;   ii) non-retroviral viral vector sequences;   iii) nucleic acid sequences coding for an exogenous gene or exogenous nucleic acid sequence; and   iv) packaging component or components for producing a non-retroviral viral vector.   
     
     
         69 . The cell line of  claim 68 , wherein said retroviral sequences i) comprise or are derived from murine leukemia virus, human immunodeficiency virus, human T cell leukemia virus and Gibbon ape leukemia virus sequences, or a combination of any of the foregoing. 
     
     
         70 . The cell line of  claim 68 , wherein said retroviral sequences i) comprise all or a part of a retroviral LTR sequence. 
     
     
         71 . The cell line of  claim 69 , wherein said human immunodeficiency virus sequence codes for gp120. 
     
     
         72 . The cell line of  claim 68 , wherein said non-retroviral viral vector sequences ii) comprise or are derived from Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Vesticular Stomatis Virus (VSV) and Adeno-Associated Virus (AAV) sequences, or a combination of any of the foregoing. 
     
     
         73 . The cell line of  claim 72 , wherein said AAV sequences comprise ITR sequences. 
     
     
         74 . The cell line of  claim 68 , wherein said non-retroviral viral vector produced by the packaging component or components iv) further comprise one or more promoters, or one or more enhancer regions, or an integration segment or a terminator. 
     
     
         75 . The cell line of  claim 74 , wherein said one or more promoters are capable of producing an RNA lacking a polyadenylation signal. 
     
     
         76 . The cell line of  claim 74 , wherein said one or more promoters comprise or are derived from a group of genes comprising snRNA, tRNA or rRNA, and a combination of any of the foregoing. 
     
     
         77 . The cell line of  claim 76 , wherein said snRNA comprises U1, U2, U3, U4, U5, U6, U7, U8, U9, U10 or U11, and a combination of any of the foregoing. 
     
     
         78 . The cell line of  claim 68 , wherein said exogenous gene or exogenous nucleic acid sequences code for a protein or an antisense sequence. 
     
     
         79 . The cell line of  claim 68 , wherein said retroviral sequences i) comprise one or more promoters sequences which have been modified. 
     
     
         80 . The cell line of  claim 79 , wherein said modification comprises a substitution or replacement or an addition to said one or more promoters sequences with an exogenous gene or exogenous nucleic acid sequence. 
     
     
         81 . The cell line of  claim 79 , wherein said exogenous gene or exogenous nucleic acid sequences code for a protein or an antisense sequence. 
     
     
         82 . The cell line of  claim 68 , wherein said cell line is derived from NIH 3T3, U937, H9 or 293, and a combination of any of the foregoing.